While Cementing Partnership With U.S. Biotech Firm, Cash-rich Simcere Launches Twin Acquisitions Targeting Biosimilar, Vaccine Outfits In China
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Fresh after cementing a new partnership with a San Francisco-based biologics firm, Simcere Pharmaceutical Group has launched twin acquisitions aimed at simultaneously expanding into the biosimilar and vaccine sectors, according to Simcere's leadership
You may also be interested in...
China's Leading Drug Outfits Gear Up To Push Development Of Biologics, Biosimilars
BEIJING - Some of China's leading innovators in drug development are laying the groundwork to become major producers of biopharmaceuticals, including reverse-engineered biosimilars, and sales of biologics have expanded speedily over the last decade
China's Leading Drug Outfits Gear Up To Push Development Of Biologics, Biosimilars
BEIJING - Some of China's leading innovators in drug development are laying the groundwork to become major producers of biopharmaceuticals, including reverse-engineered biosimilars, and sales of biologics have expanded speedily over the last decade
Simcere Subsidiary, Accused Of Illicitly Producing Substandard Rabies Vaccine, Faces Fine Of RMB 25 Million In China
HONG KONG - Simcere Pharmaceutical Group, maker of innovative drugs and branded generics, has announced disappointing first quarter results, hindered by ongoing difficulties at vaccine maker Jiangsu Yanshen Biological Technology and a sales decline for some traditional best sellers